[1]
E. Rosen and B. Spiegelman, PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth, Journal of Biological Chemistry, vol. 276, p.37731, (2001).
DOI: 10.1074/jbc.r100034200
Google Scholar
[2]
G. Krey, et al., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay, Molecular Endocrinology, vol. 11, p.779, (1997).
DOI: 10.1210/mend.11.6.0007
Google Scholar
[3]
D. Panigrahy, et al., PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis, Journal of Clinical Investigation, vol. 110, pp.923-932, (2002).
DOI: 10.1172/jci0215634
Google Scholar
[4]
J. Nedergaard, et al., PPAR [gamma] in the control of brown adipocyte differentiation, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1740, pp.293-304, (2005).
DOI: 10.1016/j.bbadis.2005.02.003
Google Scholar
[5]
C. Giaginis, et al., Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis, Expert Opin. Investig. Drugs, vol. 16, pp.1561-1572, (2007).
DOI: 10.1517/13543784.16.10.1561
Google Scholar
[6]
J. Brown and J. Plutzky, Peroxisome proliferator activated receptors as transcriptional nodal points and therapeutic targets, Circulation, vol. 115, p.518, (2007).
DOI: 10.1161/circulationaha.104.475673
Google Scholar
[7]
S. Rangwala and M. Lazar, Peroxisome proliferator-activated receptor [gamma] in diabetes and metabolism, Trends in Pharmacological Sciences, vol. 25, pp.331-336, (2004).
DOI: 10.1016/j.tips.2004.03.012
Google Scholar
[8]
A. Norris, et al., Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones, Journal of Clinical Investigation, vol. 112, pp.608-618, (2003).
DOI: 10.1172/jci17305
Google Scholar
[9]
L. Fajas, et al., PPAR [gamma] 3 mRNA: a distinct PPAR [gamma] mRNA subtype transcribed from an independent promoter, FEBS letters, vol. 438, pp.55-60, (1998).
DOI: 10.1016/s0014-5793(98)01273-3
Google Scholar
[10]
Y. Li, et al., Activation of Nuclear Receptors: A Perspective from Structural Genomics, Structure, vol. 11, pp.741-746, (2003).
Google Scholar
[11]
T. Waku, et al., Structural insight into PPAR [gamma] activation through covalent modification with endogenous fatty acids, Journal of Molecular Biology, vol. 385, pp.188-199, (2009).
DOI: 10.1016/j.jmb.2008.10.039
Google Scholar
[12]
P. Sarraf, et al., Loss-of-function mutations in PPAR [gamma] associated with human colon cancer, Molecular Cell, vol. 3, pp.799-804, (1999).
Google Scholar
[13]
A. IJpenberg, et al., Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA, Journal of Biological Chemistry, vol. 272, p.20108, (1997).
DOI: 10.1074/jbc.272.32.20108
Google Scholar
[14]
M. Hsu, et al., A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding, Journal of Biological Chemistry, vol. 273, p.27988, (1998).
DOI: 10.1074/jbc.273.43.27988
Google Scholar